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IN PURSUIT OF A MORE COMPLEX
UNDERSTANDING OF NON-MEDICAL
USE OF PRESCRIPTION DRUGS:
BROADENING PERSPECTIVE BY
SHARPENING OUR TOOLS
We appreciate the commentary by Fischer & Rehm but
would like to respond to several points they raised [1,2].
First, we agree with Fischer & Rehm that individual tra-
jectories of non-medical use of prescription drugs
(NMUPD) often begin early, with the majority of NMUPD
initiating before 21 years of age. We doubt, however, that
the trajectories from early onset of NMUPD to prescrip-
tion drug use disorders (PDUDs) are associated consis-
tently with socio-economic class or educational status.
While we were unable to assess this in the National
Epidemiologic Survey on Alcohol Related Conditions
(NESARC) because it did not measure socio-economic or
educational status at the time of NMUPD onset, previous
studies suggest that associations between these variables
are complex and vary by prescription drug class [3–5].
For instance, the non-medical use of stimulant medica-
tions is more prevalent among those with higher income
levels [3,5], while non-medical use of prescription opioids
is more prevalent among those from lower income levels
[3,4]. Individuals with higher educational levels were
more likely to engage in the non-medical use of prescrip-
tion stimulants than those with lower educational levels,
but there were no such differences for the non-medical
use of prescription opioids, sedatives or tranquilizers [3].
Secondly, we question whether most non-medical
users coming from disadvantaged circumstances are
‘self-medicators’. Being economically disadvantaged or
uninsured may limit access to prescription medication
but regardless of motivation (self-treatment versus recre-
ational use), there are notable risks for non-medical users
who self-treat. For example, ‘self-treaters’ do not receive
clinical assessments, medical follow-ups or medical
information that accompanies a prescription. Thus,
self-treaters may be unaware of contraindications or
probable interaction with other drugs. Furthermore,
abusable prescription medications can produce physical
dependence and withdrawal symptoms upon discontinu-
ation. The odds of past-year PDUDs among those who
report past-year NMUPD was considerably higher among
individuals with lower income levels than those with
higher income levels [6].
We noted the limitations of self-report measures
using life-time time-frame and expressed the hope that
prospective longitudinal studies will examine the natural
history of NMUPD. We agree with Fischer & Rehm that
more detailed measures are needed in order to obtain a
more complex understanding of NMUPD; advances in
our understanding of NMUPD will not be possible until
we reconsider the assessment tools that measure
NMUPD. Surprisingly, few advances have been made
since Hubbard and colleagues showed the limitations of
using a single measure to assess NMUPD and advocated
decomposing the single NMUPD measure into separate
questions 15 years ago [7]. Improvements in measure-
ment of NMUPD and use of prospective longitudinal
designs will help to determine if early onset of NMUPD is
simply a correlate of PDUDs or a causal risk factor [8]
that might represent a target for prevention and
intervention.
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